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ABSTRACT: Prenatal exposure to per- and polyfluoroalkyl
substances (PFAS), a ubiquitous class of chemicals, is associated
with adverse outcomes such as pre-eclampsia, low infant birth
weight, and later-life adiposity. The objectives of this study were to
examine PFAS levels in the placenta and identify sociodemographic
risk factors in a high-risk pregnancy cohort (n = 122) in Chapel
Hill, North Carolina. Of concern, PFOS, PFHxS, PFHpS, and
PFUnA were detected above the reporting limit in 99, 75, 55, and
49% of placentas, respectively. Maternal race/ethnicity was
associated with significant differences in PFUnA levels. While the
data from this high-risk cohort did not provide evidence for an
association with hypertensive disorders of pregnancy, fetal growth,
or gestational age, the prevalence of detectable PFAS in the
placenta suggests a need to biomonitor for exposure to PFAS during pregnancy. Future research should investigate factors
underlying the differences in PFAS levels in association with a mother’s race/ethnicity, as well as potential effects on pregnancy and
child health.
1. INTRODUCTION
Per- and polyfluoroalkyl acids (PFAS) are a diverse chemical
family of synthetic organic structures used for a variety of
applications in both the United States and worldwide due to
their water- and grease-resistant properties.1 PFAS are found in
fabric surface treatment, pesticides, fire-fighting foam, food
packaging, and a variety of other sources, reaching humans via
air, contaminated water, food, and breast milk.2−8 PFAS consist
of alkyl chains in which hydrogen atoms have been replaced by
fluorine. These fluorine−hydrogen bonds are exceptionally
strong, making PFAS resistant to degradation and highly
persistent in the environment and humans.9 Due to their
persistence and pervasive use, PFAS have been detected in
human blood worldwide.10,11 Between 1999 and 2012, a number
of PFAS were found at detectable levels in blood in over 98% of
the U.S. population.12,13 Concern is growing regarding wide-
spread exposure to PFAS, and a number of PFAS are currently
listed as Contaminants of Emerging Concern (CECs) by the
U.S. Environmental Protection Agency.14
PFAS exposure in pregnant women has been associated with
an increased risk of fertility problems, pre-eclampsia, and
miscarriage.15−21 In utero PFAS exposure has been associated
with an array of negative effects in children: low infant birth
weight,22−27 congenital cerebral palsy in boys,28 dysregulated
pubertal onset later in life,29 and greater adiposity.30 Animal
models have also shown deleterious effects of exposure to PFAS,
including altered pubertal onset, reduced postnatal survival, and
disturbed lactation in rodents exposed in utero.31−34 While a
number of studies have focused on pregnancy as a time window
of exposure to PFAS by assessing maternal blood or serum, few
have focused on the placenta that is critical for understanding
the effect of PFAS during pregnancy.35,36 As the transducer of
the maternal to fetal environment during pregnancy, the
placenta is important for adequate transport of nutrients,
removal of waste, and secretion of hormones. Studies have
shown that PFAS can transfer between maternal and fetal
circulation via the placenta.37−40 Additionally, the placenta:ma-
ternal serum ratios of PFAS have been found to increase with
gestational age, suggestive of the bioaccumulation of PFAS in
the placenta over time.41 Despite growing concern over the
effects of PFAS on pregnancy, fetal development, and their
ability to cross the placenta, only three studies to date, all of
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which studied women outside of the United States, have detailed
PFAS levels in the placenta.40−42 This study aimed to address
this research gap in understanding the levels of PFAS in the
placentas of a U.S.-based cohort and identify risk factors
associated with high exposure.
In addition, the majority of studies on PFAS exposure focus
on two perfluoroalkyl acids, mainly perfluorooctane sulfonate
(PFOS) and perfluorooctanoic acid (PFOA);43 however, over
3000 PFAS are estimated to be in production.1 While some of
these chemicals, including PFOS and PFOA, have been
discontinued by major manufacturers in the United States,
their persistence in the environment and continued use
internationally make them a continued toxicological concern.44
Moreover, hexafluoropropylene oxide dimer acid (HFPO-DA,
ammonium salt with trade name: GenX), a modern replacement
for PFOA, has recently contaminated drinking water from the
Cape Fear River in the Wilmington area, NC, warranting
immediate analysis of the prevalence of PFAS in NC
populations.45
In the present study, we set out to characterize the PFAS level
in the placenta and understand risk factors associated with high
PFAS exposure in a high-risk pregnancy cohort in the United
States. To carry out this research, we utilized specimens from a
cohort of pregnant women at risk for preterm birth in North
Carolina. The primary goals of this work were to (i) establish
baseline data on 22 different PFAS levels in the placenta, (ii)
identify sociodemographic risk factors associated with increased
placental PFAS levels in this cohort, and (iii) investigate whether
PFAS placental levels change with gestational age at delivery,
fetal growth, or hypertensive disorders of pregnancy (pre-
eclampsia and gestational hypertension).
2. MATERIALS AND METHODS
2.1. Study Population. This cross-sectional study was
derived from the UNC Preterm Birth Biobank (PTB) Study.46
The original purpose of this overarching study was to establish a
database and tissue bank to evaluate clinical and biochemical
markers of preterm birth. Participants were identified and
recruited through UNC-CH obstetrics and gynecology clinics
and inpatient obstetric units at the North Carolina Women’s
Hospital from 2015 to 2018. Women at high risk for
spontaneous preterm birth due to (a) a prior spontaneous
preterm birth, (b) short mid-trimester transvaginal cervical
length (<25 mm, assessed between 16.0 and 23.9 weeks’
gestation) in the current pregnancy, (c) twin or triplet gestation,
or (d) antepartum admission due to threatened preterm labor
following cervical change and/or cervical dilation in the setting
of at least six symptomatic uterine contractions per hour were
included in the UNC PTB Biobank. Women carrying fetuses
with major structural anomalies or aneuploidy were excluded.
Pregnancies were dated by the last menstrual period (if
available) and ultrasound using standard American College of
Obstetricians and Gynecologists criteria.47 All pregnancy
management decisions were made at the discretion of the
primary obstetric provider. This study was approved by the
Institutional Review Board of the University of North Carolina,
Chapel Hill (IRB# 14-2855), and all women provided written,
informed consent.
Baseline clinical and demographic information (including
maternal educational attainment, race and ethnicity, marital
status, and prepregnancy body mass index (kg/m2)) were
collected from participants through structured interviews and
supplemented by a review of electronic medical records. In
addition, the antenatal course, delivery indications, and
pregnancy outcomes (including infant gender, birth weight,
gestational age at delivery) were obtained from the electronic
medical record following delivery.
After delivery, three full-thickness placental biopsies were
obtained from the fetal side, 2 cm from the placental cord
insertion site using a standard 3 mm punch biopsy tool, and
frozen at −80 °C within 24 h of delivery until analysis. Care was
taken to avoid biopsies of placental sites with obvious gross
abnormalities. Two hundred and seventy-one women were
enrolled in the UNC PTB Biobank study: 2 had a first-trimester
miscarriage, 13 were lost to follow-up or had missing data on
gestational age at delivery, resulting in 256 viable placentas, of
which 122 had enough remaining placental sample to be used in
the present analysis.
2.2. Placenta PFAS Quantification. Extraction and
quantification by liquid chromatography−mass spectrometry
(LC−MS/MS) method established utilized in this study were
previously established in Bangma et al. 2018 and included 15
total PFAS.48 In the current study, the method was updated to
include a total of 22 PFAS as follows: perfluorobutyric acid
(PFBA), perfluoropentanoic acid (PFPeA), perfluorohexanoic
acid (PFHxA), perfluoroheptanoic acid (PFHpA), perfluor-
ooctanic acid (PFOA), perfluorononanoic acid (PFNA),
perfluorodecanoic acid (PFDA), perfluoroundecanoic acid
(PFUdA), perfluorododecanoic acid (PFDoA), perfluorotride-
canoic acid (PFTrDA), perfluorotetradecanoic acid (PFTeDA),
perfluorohexadecanoic acid (PFHxDA), perfluorobutanesul-
fonic acid (PFBS), perfluoropentanesulfonic acid (PFPeS),
perfluorohexanesulfonic acid (PFHxS), perfluoroheptanesul-
fonic acid (PFHpS), perfluorooctane sulfonic acid (PFOS),
perfluorononanesulfonic acid (PFNS), perfluorodecanesulfonic
acid (PFDS), perfluorododecancesulfonic acid (PFDoS),
1H,1H,2H,2H-perfluorooctane sulfonic acid (6:2 FTS), and
2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)-
propanoic acid (HFPO-DA also known as GenX). In-depth
information detailing the Bangma et al. 2018 method as it was
utilized for placenta PFAS quantification can be found in the
Supporting Information (SI).
2.3. Statistical Analysis. PFHpS, PFHxS, PFOS, and
PFUnA were identified as having approximately 50% or more
of samples over the reporting limit (RL). Using an established
gravimetric method, the reporting limit (RL) is calculated in two
ways: (1) using the lowest detectable calibrant divided by the
mass of the extracted sample or (2) taking the average amount of
compound detected in the blanks divided by the mass of the
extracted sample.49,50 To be conservative, from the twomethods
of calculating the RL, the RL that was the highest for that PFAS
and sample was designated as the respective RL for PFAS in that
sample (Supporting Information File S1). The concentrations
determined include isomers for applicable PFAS. For statistical
analysis, all samples below the RL were set to half the RL
detection limit for that sample and PFAS.51 This allowed for the
preservation of sample size for the PFAS included in the
statistical analysis. Spearman rank correlations between
concentrations of each of the PFAS were calculated to evaluate
patterns of co-occurrence.
For this analysis, the race was categorized as non-hispanic
white, hispanic white, non-hispanic black, or other. Education
was trichotomized into less than high school, completed high
school, or further education beyond high school. Marital status
was dichotomized as married or not married. Delivery
gestational age was maintained as a continuous variable for
regression analyses andwas also trichotomized into very preterm
(delivery before 340/7 weeks of gestation), preterm (delivery
between 340/7 and 366/7 weeks of gestation), and term (delivery
≥ 370/7 weeks of gestation) for a categorical variable. Insurance
was trichotomized into private insurance, Medicaid/Medicare
insurance, or self-pay. Maternal age was trichotomized into
below 20 years old at delivery (<20 years), between 20 and 35
years of age at delivery (≥20 to <35 years), and over 35 years and
older at delivery (≥35 years). Prepregnancy BMI was
categorized into underweight (BMI <18.5 kg/m2), normal
weight (≥18.5−24.9 kg/m2), overweight (≥25.0−29.9 kg/m2),
and obese (≥30.0 kg/m2) categories. Gestational hypertension
was defined as new-onset hypertension, with at least two blood
pressure readings≥ 140/90 at least 6 h apart at or after 20 weeks’
gestation. Pre-eclampsia was defined as hypertension accom-
panied by new-onset proteinuria (urine protein:creatine ratio
≥0.30 or 24 h urine protein ≥ 300 mg/dL) and/or laboratory
abnormalities (platelet count <100 per microliter, serum
aspartate transaminase, or aminotransferase twice normal or
≥70 U/L) and/or severe headache or visual disturbance.
Women with chronic hypertension were considered to have
super-imposed pre-eclampsia if they had an exacerbation of their
hypertension in addition to one of the above laboratory
abnormalities or physical symptoms. Because the American
College of Obstetricians and Gynecologists recognize that pre-
eclampsia can develop in the absence of proteinuria, and the
management of gestational hypertension and pre-eclampsia is
similar, these diagnoses were combined into one “hypertensive
disorders of pregnancy” variable, dichotomized as yes or no.47
For assessing the association with fetal growth, small for
gestational age (SGA), appropriate for gestational age (AGA),
and large for gestational age (LGA) newborns were identified
using gender-specific fetal growth curves from a nationally
representative, racially diverse reference population. Small for
gestational age was defined as birth weight in grams ≤10th
percentile and large for gestational age was defined as birth
weight in grams≥ 90th percentile of this reference population.52
Those born <23 weeks’ gestation were considered as having
missing data for fetal growth category because there is no
nationally representative data on birth weight distributions
below this gestational age from the reference used. Smoking
status was not included in analyses as only 9 mothers reported
active smoking during pregnancy and 112 mothers reported
nonsmoking status.
Distributions of each PFAS were evaluated for normality via
Shapiro−Wilks tests of both original and log-transformed data.
All PFAS evaluated were determined to have non-normal
distributions in both original and log-transformed forms; thus,
to examine differences across categorical variables, non-
parametric tests were employed to test the equality of medians.
Wilcoxon tests were used to evaluate differences between
dichotomous sociodemographic variables and hypertensive
disorders of pregnancy, and Kruskal−Wallis tests were used to
evaluate differences between sociodemographic variables with











white, non-hispanic 42 (37.5)
white, hispanic 30 (26.8)
black, non-hispanic 37 (33.0)
other 3 (2.7)
maternal smoking 1 (<1)
yes 9 (7.4)
no 112 (92.6)









18.5 ≤ 25 24 (19.7)
25 ≤ 30 30 (24.6)
30+ 62 (50.8)
maternal age 20−44 31.0
(6.51)
1 (<1)
below 20 years old
(<20)
0 (0)
between 20 and 25 years
old (≥20 to <35)
77 (63.1)
















less than high school 13 (12.8)
completed high school 42 (41.2)
more than high school 34 (33.3)
declined 13 (12.8)
marital status 8 (6.6)
married 81 (71.0)
not married 33 (29.0)








(34 ≤ weeks <37)
12 (9.9)












birth weight (grams) 159−4300 2375
(1085)
5 (4.1)







aPercent of nonmissing observations. bPercent of all observations.
more than two groups and fetal growth categories. The p-values
of these tests are reported with significance defined as p < 0.05.
To evaluate whether PFAS levels varied by gestational age,
both univariate and multivariate linear regression models were
performed to generate crude and adjusted estimates of change in
PFAS levels by gestational age. For the multivariate linear
regression, control variables were identified as having significant
or borderline significant differences in medians across groups
from the sociodemographic risk factor analysis described above.
To assess temporal changes in PFAS concentrations of the
placenta, univariate linear regression models were used to
evaluate the association between delivery date and PFAS
concentration. For this model, births in 2018 were excluded due
to a low sample size (n = 2 births in 2018). All analyses were
conducted in SAS 9.4 software.
3. RESULTS
3.1. Study Population Characteristics. This cohort of
122 women included 42 (37.5%) non-hispanic white, 30
(26.8%) hispanic white, 37 (33.0%) non-hispanic black, and 3
(2.7%) women who self-reported other for race/ethnicity
(Table 1). The majority (63.1%) of women were between 20
and 34 years old. Just over half (53.9%) had private medical
insurance, with 38.5% using Medicaid/Medicare insurance. In
this high-risk group, the mean gestational age at delivery was
33.9 weeks. A total of 44 women (36.9%) delivered very preterm
(less than 34 weeks), 12 women (9.8%) delivered preterm
(between 34 and 37 weeks), and 65 women (53.3%) delivered
term (37 weeks or over). Fourteen (11.5%) women had
pregnancies complicated by hypertensive disorders. The mean
birth weight was 2,375 g (range 159−4300 g). In comparison to
the National Vital Statistics data from 2016 and 2017
representatives of all births in the United States, the present
cohort differs slightly with regard to racial demographics (U.S.
population, 2017: 51.68% white mothers, 14.54% to non-
hispanic black, 23.3% hispanic) but is similar with regard to the
percentage of insurance types (U.S. population, 2017: 49.1%
private insurance, 43% Medicaid).53,54 As expected, given the
high-risk characteristics of the cohort, the mean gestational age
at delivery (prevalence of preterm births) and mean birth weight
differed from the general U.S. population.53,54
3.2. PFAS Levels in the Study Population. Of the 22
PFAS examined in the placenta, 11 PFAS were detected in at
least one placenta sample (n = 122) (Table 2). Compared to
three other non-U.S.-based studies of placenta PFAS levels,
these data are relatively consistent, with PFOS and PFOA found
at the maximum values (Figure 1). PFHxS, PFHpS, PFOS, and
PFUnA were detected over the RL in approximately 50% or
more of samples. As a significant lack of detection would skew
results, for all subsequent analyses, only these four PFAS are
considered and values below the RL were imputed as half the
RL. The highest levels detected were of PFOS, followed by
PFHxS, PFUnA, and then PFHpS (Figure 2). PFOS was
detected at a median of 0.480 ng/g and amaximum of 4.87 ng/g.
Comparatively, PFHxS had a median of 0.067 ng/g and a
maximum of 0.446 ng/g and PFUnA had a median value under
the RL and a maximum of 0.240 ng/g. PFHpS was found to have
a median concentration of 0.009 ng/g and a maximum of 0.063
ng/g. Correlation between the levels of PFHxS, PFHpS, PFOS,
and PFUnA was common (Supporting Information Figure S1
and Table S1). Specifically, all pairings other than PFUnA and
PFHxS were significantly positively correlated. The most
significant correlation was PFHpS and PFHxS (Spearman
correlation coefficient = 0.532, p-value = 2.907 × 10−10).
The median and interquartile ranges of PFAS in the total
cohort and stratified by select sociodemographic characteristics
were calculated (Table 3). Median and interquartile ranges for
the remaining sociodemographic characteristics can be found in
the Supporting Information Table S2. Additionally, p-value
results of Wilcoxon or Kruskal−Wallis test for difference in
median levels are displayed. Two comparisons were statistically
significant (p < 0.05). PFUnA levels in the placenta were
significantly different according to race/ethnicity status (p =
0.0002). One comparison was approaching the statistical
significance: difference in PFHpS levels in the placenta in
mothers of different ages (p = 0.0936).
3.3. PFAS Levels and Race/Ethnicity. Significant differ-
ences in PFUnA levels were observed by maternal race and
Table 2. Of 22 Monitored PFAS, 11 That Were Detected in PTB Biobank Placenta (n = 122) Are Shown Herea,b
PFPeS PFHxSc PFHpSc PFOSc PFHxA PFOA PFNA PFDA PFUnAc PFTriA PFTA
chain length 5 6 7 8 6 8 9 10 11 13 14
n 122 122 122 122 122 122 122 122 122 122 122
% >RL 31 75 55 99 1.6 27 21 39 49 29 7
maximum (ng/g) 0.035 0.446 0.063 4.87 5.87 1.23 0.494 0.465 0.240 0.336 0.111
minimum (ng/g) <0.005 <0.033 <0.008 <0.001 <1.32 <0.290 <0.148 <0.030 <0.033 <0.050 <0.049
median (ng/g) <0.005 0.067 0.009 0.480 <1.45 <0.315 <0.163 <0.031 <0.031 <0.057 <0.054
aPFAS with approximately 50% or more of samples above the reporting limit (RL) were included in the statistical analysis. bValues below the RL
are listed in this table as “<RL”. cIncluded in the statistical analysis.
Figure 1.Maximum, minimum, andmedian (means are indicated when
medians were not reported in the literature) PFAS levels measured by
ng/g wet weight in the human placenta as reported in the literature for
Chen et al. 2017 (n = 32), Mamsen et al. 2019 (n = 78), Mamsen et al.
2017 (n = 34, means reported), and placentas included in the current
study, Bangma et al. (n = 122). Frequently reported PFAS, including
PFOS, PFOA, PFNA, and PFDA, were included in the graph as well as
any additional PFAS detected in ∼50% of the placenta in the current
study, including PFUnA, PFHxS, and PFHpS.
ethnicity. The three women of other race/ethnicities had the
highest maximum and median values: 0.156 and 0.081 ng/g,
respectively. This was followed by hispanic white, non-hispanic
white, and non-hispanic black women, according to their median
value. No other comparisons of PFAS levels by race/ethnicity
were significant, and the order from the highest to lowest median
values was not consistent across the different PFAS.
3.4. PFAS Levels and Maternal Age. Differences by
maternal age in PFHpS were trending toward significance (p =
0.09). Older mothers were observed to have higher levels of
PFHpS than younger mothers. The median PFHpS in mothers
under 20 years old was 0.004 ng/g, mothers between 20 and 35
years old had a median level of 0.009 ng/g, and mothers over the
age of 35 had a median level of 0.011 ng/g.
3.5. PFAS Levels and Hypertensive Complications of
Pregnancy. No significant differences in PFHxS, PFHpS, or
PFOS by hypertensive disorders of pregnancy were found
(Supporting Information Table S3). A borderline significant
difference was observed of PFUnA levels by hypertensive
complications of pregnancy status (p = 0.09). In women with
hypertensive complications of pregnancy, the median PFUnA
level was 0.044 ng/g, compared to 0.020 ng/g in women without
hypertensive complications of pregnancy. All median values
were higher in placentas of mothers with hypertensive
complications of pregnancy. Associations were examined in a
sex-specific manner (e.g., stratified by fetal sex), and no
significant differences were observed (data not shown).
3.6. PFAS Levels and Fetal Growth. Fetal growth was
categorized into small for gestational age (SGA), appropriate for
gestational age (AGA), and large for gestational (LGA). Of the
cohorts, 8.0% was SGA and 10.6% was LGA. No significant
differences in median placental levels of PFOS, PFHxS, PFHpS,
nor PFUnA were seen by fetal growth categories (Supporting
Information Table S4). No consistent patterns were seen for
PFAS levels across fetal growth categories. Associations were
examined in a sex-specific manner (e.g., stratified by fetal sex),
and no significant differences were observed (data not shown).
3.7. PFAS Levels and Gestational Age. Gestational ages
in this cohort ranged from 18 to 41 weeks. Both crude and
adjusted linear regression models regressing PFAS level onto
gestational age showed no significant association (Supporting
Information Table S5A,B). β values representing the predicted
change in the PFAS level in μg/g with each additional week of
gestation were positive for PFHxS and PFHpS (increase in the
placental PFAS level with an increase in gestational age) and
negative for PFOS and PFUnA (a decrease in the placental
Figure 2. Whisker plots of the distribution of PFAS of the four PFAS
included in statistical analysis: PFHpS, PFHxS, PFOS, and PFUnA.

















































































































































































































































































































































































































































































































































































































































































































































































































































































PFAS level with an increase in gestational age) in both the crude
and adjusted models.
For the remaining seven PFAS detected below 50% RL,
associations between gestational age and detection of PFAS
above the RL were investigated utilizing unadjusted binomial
regression models. PFAS levels were dichotomized into two
categories (detected above RL or detected below RL). PFOA
was significantly more likely (p = 0.04) to be detected above RL
in later gestational ages compared to that in earlier gestation age
placentas (Supporting Information Table S6). Associations were
examined in a sex-specific manner (e.g., stratified by fetal sex),
and no significant differences were observed (data not shown).
3.8. PFAS Levels Over Time (Year of Delivery). Dates of
birth in this cohort ranged from 04/12/2015 to 01/12/2018. As
only two participants had births in 2018, for the analysis of the
effect of year of delivery, these two observations were removed.
PFOS, PFHxS, and PFUnA were all found to decrease in
concentration in placental tissues over time (Supporting
Information Table S7). However, only PFHxS significantly
decreased over time, with a predicted change with each passing
year of −0.024 ng/g (p-value = 0.04). PFHpS showed an
increase in levels with each subsequent year; however, this
association was not significant.
4. DISCUSSION
PFAS exposure during pregnancy has been associated with
health risks for both the mother and the fetus.15,16,20,22,26,27,30,55
Despite growing concern over the effects of prenatal exposure to
PFAS, and the understanding that PFAS can cross the maternal
fetal barrier via the placenta, a limited number of studies have
evaluated PFAS levels in the placenta.37−40 Investigating the
placenta separately from maternal serum can lend additional
information as to the extent to which PFAS accumulate in the
placenta. This is particularly important because it cannot be
assumed that serum concentrations are representative of PFAS
accumulation in specific critical organs. For example, studies
have observed certain PFAS in higher levels in brain and lung
compartments despite low rates of detection in serum.56 The
present study provides novel information as it is among the first
to quantify and analyze placental levels of PFAS in a U.S. cohort.
Overall, there were three major findings. First, many of the
placental samples had levels of specific PFAS chemicals similar
to international studies. Of concern, PFOS, PFHxS, PFHpS, and
PFUnA were detected above the reporting limit in 99, 75, 55,
and 49% of placentas, respectively. Second, placental PFAS
levels varied by race/ethnicity for PFUnA. Finally, associations
between the levels of PFAS in the placenta in the study cohort
and gestational age, hypertensive disorders of pregnancy, and
fetal growth were performed but did not reach statistical
significance. While placental PFAS were not associated with
pregnancy or child health outcomes in this high-risk cohort, the
prevalence of their detection in the placenta suggests a need to
biomonitor during pregnancy.
Of the four PFAS detected above RL in approximately 50% or
more of samples, PFOS was found in the highest concentration.
This finding is consistent with the current literature. Previously
published studies on PFAS in the placenta are limited to three
studies: one in China and two in Denmark.40−42 Similar to the
results from the present study, these studies found PFOS and
PFOA as having the highest and second highest median ng/g
wet weights, respectively, compared to other PFAS. Moreover,
in the analysis of PFAS in serum measured by the National
Health and Nutrition Examination Survey (NHANES) from
1999 to 2016, PFOS was consistently found in the greatest
concentration compared to other PFAS.57 Notably, of the four
PFAS detected above RL in the present study, only PFOS and
PFHxS are currently tracked by NHANES; therefore,
comparison to the general US population for exposure to
PFHpS and PFUnA is not possible at this time. InNHANES, the
geometric means in the serum of PFOS and PFHxS (2015−
2016) are 4.72 and 1.18 μg/L, respectively.57 Despite PFOS
being phased out of production in the United States since
2002,57,58 the presence of PFOS in the placenta in this study
highlights the persistence of PFAS and signifies the importance
of continued PFAS monitoring and reduction efforts.
In the present study, maternal race and ethnicity were
associated with significant differences in PFUnA levels, with
those who self-reported their race/ethnicity as other than non-
hispanic white, hispanic white, and non-hispanic black having
the greatest measured median wet weight in ng/g of PFUnA,
while non-hispanic black women had the lowest. PFAS
concentrations have been found to vary by race/ethnicity in
nonpregnancy cohorts; however, consistent patterns have not
been established and different PFAS appear to demonstrate
varied distributions by race and ethnicity.59−61 Research
concerning associations between race/ethnicity and PFAS levels
in pregnant women is limited. To our knowledge, the only
studies to investigate race/ethnicity and PFAS in pregnant U.S.
women are the Health Outcomes and Measures of the
Environment (HOME) Study and Project Viva. The HOME
study observed significantly different serum PFAS concen-
trations in pregnant mothers based on maternal race.36,62,63 In
addition, both Project Viva and the HOME Study found that
maternal race can be a predictor of PFAS levels in children, with
children born to black mothers showing lower PFAS levels than
children born to white mothers.62−64 Additional research on the
relationship between PFAS levels and maternal race and
ethnicity is warranted to discern environmental exposure
disparities, sources, and pathways.
Finally, this study evaluated changes in PFAS with gestational
age at birth and pre-eclampsia or gestational hypertension.
Previously, Mamsen and colleagues investigated placentas in the
first through third trimester and identified five PFAS, including
PFOS, PFOA, PFDA, PFNA, and PFUnA, that increased as
gestational age increased.41,42 In the present study, none of the
PFAS displayed a significant association between PFAS levels
and gestational age. The differences between the Mamsen
studies and the current study could be due to several factors.
First, this high-risk cohort is enriched with placentas from
preterm deliveries compared to the larger U.S. population. As a
result, the placentas are likely physiologically distinct from term
placentas, which may influence PFAS accumulation.65,66
Second, the current study investigated placentas from mid-
second to third trimester pregnancies (18−41 weeks’ gestation),
while Mamsen et al. investigated placentas from the first to third
trimesters. Third, our study cohort placentas were obtained
from live births, while the Mamsen studies investigated PFAS in
the placenta and fetal organs from intrauterine fetal demise
(IUFD). In addition, in the present study, we observed no
associations between pre-eclampsia or gestational hypertension
and placental PFAS. Previous literature is divided on the subject
of PFAS and pre-eclampsia with one study reporting no
association,17 while other studies report associations for at
least one PFAS, including PFOS, PFOA, PFNA, and
PFBS.15,16,19,20 It is important to note that placental studies
are limited to cross-sectional design and therefore hindered by
the potential for reverse causality.67,68
While this study is among the first to examine PFAS placental
levels in a U.S. cohort, it is not without limitations.
Concentrations of PFAS quantified in the placenta are usually
lower than matching fetal cord serum and maternal serum.40
This limitation often reduces the number of PFAS measured
above the reporting limit and can impact the ability of
researchers to identify associations between PFAS and potential
risk factors; for example, PFUnA, in our study, was detected
above the RL in 49% of placentas. Future studies will investigate
PFAS in matching maternal serum from this cohort. Finally, the
cohort used in this study comprises women at high risk for
spontaneous preterm birth in North Carolina. As mentioned,
the exposure levels and associations detected in this cohort are
likely not generalizable to the broader U.S. population of
pregnant women due to the geographical and obstetric
characteristics of this cohort.69 Specifically, pathologies of the
placenta may influence bioaccumulation of PFAS, and thus,
reverse causality cannot be excluded with a cross-sectional study.
Future research should investigate the associations between
PFAS accumulation in the placenta and pregnancy complica-
tions in a more generalizable cohort.
For the 122 placentas investigated, similar PFOS and PFOA
levels were observed in this U.S.-based cohort as compared to
cohorts in China and Denmark. Maternal race/ethnicity was
associated with significant differences in PFUnA levels. No
significant associations between PFAS and fetal growth,
gestational age, or hypertensive disorders of pregnancy were
observed in the current study. Overall, this study expands on the
limited data describing PFAS levels in the placenta and further
highlights the need for biomonitoring of PFAS during pregnancy
among women of child-bearing age.
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